Christian E. Rothe

CFO

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 1 buy · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€1.6M

▼ Sales (1 ops.)

€219k

Latest filing published 21 Aug 2026 for Rockwell Automation, INC. Read the official filing

Filing timeline

BuySale

Christian E. Rothe

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Christian E. Rothe: trading record in brief

This profile gathers the share dealings of Christian E. Rothe across 2 companies, led by Rockwell Automation, Inc and Graco Inc. The record holds 7 filings, for trades running from 23 February 2024 to 20 August 2026.

On the open market, the record shows 1 purchase worth €1.6M and 1 sale worth €219k. Netting one side against the other leaves €1.4M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 5 option exercises. 2026 to date brings no purchases and 1 sale.

The latest filing, published on 21 August 2026, reports an option exercise in Rockwell Automation, Inc. The most recent open-market purchase was published on 12 November 2024, 705 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.